33rd Annual Report FY: 2024-25
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Samrat Pharmachem Limited has filed its 33rd Annual Report for FY 2024-25 along with the notice of its 33rd Annual General Meeting, as required under SEBI Listing Regulations. The AGM is scheduled for Thursday, September 25, 2025 at 1:00 p.m. via video conferencing, with the record date/cut-off date set as September 18, 2025 and remote e-voting open from September 22 to September 24, 2025. The Board has recommended a final dividend of ₹1.00 per equity share (face value ₹10) for FY 2024-25, subject to shareholder approval. Key resolutions include re-appointment of Mr. Lalit Mehta as Chairman & Managing Director, Mr. Rajesh Mehta and Mr. Megh Mehta as Executive Directors (all for the period April 1, 2026 to March 31, 2031), appointment of Mr. Piyush Dharod as a Non-Executive Independent Director, and appointment of Mr. Aqueel Mulla as Secretarial Auditor for five years from FY 2025-26 to FY 2029-30. The company has also noted a change of its Registrar and Share Transfer Agent from Link Intime to MUFG Intime India Private Limited effective December 31, 2024.
This is a routine regulatory filing covering AGM-related disclosures; the proposed ₹1 per share dividend is modest and reflects steady shareholder returns. Re-appointment of all three promoter-led executive directors signals management continuity with no leadership change expected in the near term.